Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.

Company Guidance

In the Ardelyx Fourth Quarter and Fiscal Year 2024 earnings call, the company provided guidance on its financial expectations and strategic priorities for 2025 and beyond. The company reported total revenues of $333.6 million for 2024, a significant increase from $124.5 million in the previous year, driven by the growth of IBSRELA and the launch of XPHOZAH. IBSRELA achieved a 32% quarter-over-quarter growth rate in Q4 and is projected to generate between $240 million and $250 million in net product sales revenue in 2025, with a long-term goal of exceeding $1 billion in annual sales prior to patent expiry. XPHOZAH, which achieved $160.9 million in annual sales in 2024, is projected to reach $750 million in annual net sales before patent expiry. The company ended the year with a strong cash position of $250.1 million, bolstered by $49.7 million in proceeds from a term loan agreement, and plans to strategically invest in expanding its commercial and patient services teams to drive continued growth.

IBSRELA Growth

IBSRELA reported a more than 32% growth quarter-over-quarter from Q3 of the same fiscal year, demonstrating strong demand and successful sales-force expansion.

XPHOZAH Launch Success

XPHOZAH achieved $57.2 million in net product sales revenue for the fourth quarter, marking an 11% increase over Q3, highlighting its importance in treating hyperphosphatemia.

Strong Financial Position

Ardelyx ended the fiscal year with $250 million in cash, cash equivalents, and short-term investments, an increase from $184.3 million at the end of 2023.

Year-Over-Year Revenue Growth

The company reported total revenues of $333.6 million for 2024, compared to $124.5 million in the prior year, driven by IBSRELA and XPHOZAH sales.

Positive Net Income

Ardelyx reported a net income of approximately $4.6 million for the fourth quarter, compared to a net loss of $28.8 million in the same period of the prior year.

---

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 20, 2025	2024 (Q4)	<0.01 / 0.02	-0.12	116.67% (+0.14)	―	―
Oct 31, 2024	2024 (Q3)	-0.05 / 0.00	0.03	―	―
Aug 01, 2024	2024 (Q2)	-0.11 / -0.07	-0.08	12.50% (<+0.01)	―
May 02, 2024	2024 (Q1)	-0.15 / -0.11	-0.13	15.38% (+0.02)	―
Feb 22, 2024	2023 (Q4)	-0.10 / -0.12	0.06	-300.00% (-0.18)	―
Oct 31, 2023	2023 (Q3)	-0.11 / 0.03	-0.14	121.43% (+0.17)	―
Aug 02, 2023	2023 (Q2)	-0.12 / -0.08	-0.19	57.89% (+0.11)	―
May 03, 2023	2023 (Q1)	-0.10 / -0.13	-0.21	38.10% (+0.08)	―
Mar 02, 2023	2022 (Q4)	<0.01 / 0.06	-0.31	119.35% (+0.37)	―
Nov 03, 2022	2022 (Q3)	-0.17 / -0.14	-0.42	66.67% (+0.28)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ARDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 20, 2025	$6.36	$5.72	-10.06%
Oct 31, 2024	$5.87	$6.09	+3.75%
Aug 01, 2024	$5.50	$6.05	+10.00%
May 02, 2024	$6.79	$8.72	+28.42%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---